预约演示

更新于：2025-08-12

Meropenem

美洛培南

更新于：2025-08-12

概要

基本信息

药物类型

小分子化药

别名

Belopenem、Mepem、Meropen

+ [23]

靶点

PBPs

作用方式

抑制剂

作用机制

PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂)

治疗领域

感染神经系统疾病消化系统疾病+ [8]

在研适应症

复杂腹腔感染细菌性脑膜炎（非特异性）化脓性脑膜炎+ [27]

非在研适应症

蜂窝织炎呼吸机相关性肺炎

原研机构

Sumitomo Pharma Co., Ltd.

在研机构

Sumitomo Pharma Co., Ltd.

Pfizer Australia Pty Ltd.

B. Braun Medical, Inc.

+ [3]

非在研机构

Melinta Therapeutics, Inc.

Matinas BioPharma Holdings, Inc.

Pfizer Inc.

+ [1]

权益机构

上药康德乐（上海）医药有限公司

AstraZeneca PLC

Pfizer Inc.

+ [1]

最高研发阶段批准上市

首次获批日期

日本 (1995-06-30),

附件炎关节炎胆管炎+ [16]

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C17H27N3O6S

InChIKeyWCDAAZJSDNCCFU-NACOAMSHSA-N

CAS号119478-56-7

关联

174

项与美洛培南相关的临床试验

NCT07096310

/ Not yet recruiting临床1/2期IIT

Comparison Between Carbapenems and Noncarbapenem Broad Spectrum Beta-lactam Antibiotics as Initial Antibiotic Therapy Against Sepsis in Burn Patients: A Prospective Study

The aim of this work is to evaluate the efficacy associated with Meropenem(example of carbapenems) as initial therapy for sepsis in burn patients compared with Pipracillin/Tazobactam (example of non carbapenem beta lactam antibiotics).

开始日期2025-08-01

申办/合作机构

Ain Shams University

NCT06184659

/ Recruiting临床4期IIT

Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (EMPRESS) Trial

The EMPRESS trial aims to test the two most commonly used antibiotics (meropenem and piperacillin/tazobactam) among intensive care patients with sepsis (blood poisoning), as the safety of these two drugs is unclear in this group of patients.

开始日期2025-06-26

申办/合作机构-

CTIS2024-516360-29-00

/ Recruiting临床2期

A Multi-Center, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vabomere (meropenem-vaborbactam) in the Treatment of Children with Complicated Urinary Tract Infection, Including Acute Pyelonephritis - ML-VAB-201-3248-2

开始日期2025-06-03

申办/合作机构

Rempex Pharmaceuticals, Inc.

100 项与美洛培南相关的临床结果

登录后查看更多信息

100 项与美洛培南相关的转化医学

登录后查看更多信息

100 项与美洛培南相关的专利（医药）

登录后查看更多信息

25,608

项与美洛培南相关的文献（医药）

2026-01-01·TALANTA

A fluorescent sensor based on nitrogen-doped graphene quantum dots and molecularly imprinted polymers for selective and sensitive detection of meropenem in environmental and clinical matrices

Article

作者: Almalki, Atiah H ; Ramzy, Sherif ; Alaqel, Saleh I ; Alzhrani, Rami M ; Alosaimi, Manal E ; Abdelazim, Ahmed H ; Alnemari, Reem M ; Althobaiti, Yusuf S ; Serag, Ahmed ; Abduljabbar, Maram H

Meropenem, a broad-spectrum carbapenem antibiotic, is widely used in the treatment of severe bacterial infections. However, the accurate determination of meropenem in complex biological and environmental matrices remains a significant analytical challenge. In this study, we report the development of a highly sensitive and selective fluorescence sensor for the determination of meropenem using nitrogen-doped graphene quantum dots capped with a surface molecular imprinting polymer (N-GQDs@MIP). Characterization and optical properties of the N-GQDs@MIP nanocomposite were thoroughly investigated using various analytical techniques. Upon excitation at 365 nm, the sensor exhibited strong fluorescence emission at 450 nm which quenched upon meropenem binding. Mechanistic studies revealed a static quenching process driven by strong host-guest interactions between meropenem and the imprinted polymer recognition sites, as confirmed by Stern-Volmer analysis and thermodynamic calculations. Density functional theory calculations also revealed specific molecular interactions between meropenem and the N-GQDs@MIP. Central composite design optimization was employed to systematically investigate the effect of key experimental parameters, such as pH, reaction time, and N-GQDs@MIP concentration, on the sensor's performance. A significant quadratic regression model was obtained, with a high coefficient of determination (R² = 0.956) and excellent predictive capability that was further employed to maximize the sensor's sensitivity. Validation of the analytical method demonstrated a wide linear range of 25-1500 ng/mL, a low limit of detection of 7.42 ng/mL, and excellent selectivity against structurally similar antibiotics as well as good stability and reusability. The developed N-GQDs@MIP sensor was successfully applied to the determination of meropenem in pharmaceutical formulations, spiked human serum, urine, and environmental water samples with satisfactory recoveries and precision. Hence, this facile and robust fluorescence sensor offers a promising analytical platform for the sensitive, selective, and reliable quantification of meropenem in various clinical and environmental applications posing the current approach as a valuable alternative to existing analytical methods.

2025-12-31·Emerging Microbes & Infections

Scarless excision of an insertion sequence in the OmpK36 promoter restores meropenem susceptibility in a non-carbapenemase-producing Klebsiella pneumoniae

Article

作者: Yuan, Yinghua ; Gong, Yuanzhi ; Wang, Sheng ; Zhu, Yunlou ; Du, Yingying ; Liu, Tong ; Liu, Yuhao ; Hao, Min

Carbapenem-resistant Klebsiella pneumoniae (CRKP) poses a significant global health challenge due to its limited treatment options and high mortality rates. Meanwhile, the prevalence of non-carbapenemase-producing CRKP (NC-CRKP) strains is increasing, but their resistance mechanisms remain less understood compared to those of carbapenemase-producing CRKP (CP-CRKP). In this study, KP-469, an NC-CRKP strain, was found to lack the major porins OmpK35 and Ompk36 but possessed OmpK37, coexisting with ESBL resistance genes CTX-M and SHV. Membrane porin coding sequence alignment revealed a minor deletion in Ompk35 and a 768 bp insertion sequence in the promoter region (IS-PR) of Ompk36, located between the -10 region and the ribosome-binding site (RBS). In the KO-469 strain with scarless excision of IS-PR and the constructed pHSG396-promoter-Ompk36 strain that incorporated wild-type Ompk36 promoter into KP-469, the transcription levels of Ompk36 were significantly higher than that in KP-469 strain, and His-tag antibody quantification further confirmed the regular expression of Ompk36 in KO-469. These results demonstrated that IS-PR markedly reduced the transcriptional and translational efficiency of Ompk36 in the KP-469 strain, leading to decreased permeability to meropenem. Moreover, the restored susceptibility to meropenem in the KO-469 strain was validated by in vitro antimicrobial susceptibility tests and an in vivo intraperitoneal infection model constructed in neutrophil-depleted mice. The novel carbapenem resistance mechanism of NC-CRKP caused by the insertion sequence in the OmpK36 promoter will facilitate the development of antibacterial regimens for treating NC-CRKP infections.

2025-12-31·Emerging Microbes & Infections

The emergence of highly resistant and hypervirulent Escherichia coli ST405 clone in a tertiary hospital over 8 years

Article

作者: Sun, Zhifei ; Zhao, Shuping ; Du, Hong ; Jiang, Meijie ; Chen, Liang ; Wang, Min ; Zhang, Zhijun ; Wang, Xinying ; Zhu, Jie ; Feng, Qiang

The emergence of carbapenem-resistant Escherichia coli (CREC) poses crucial challenges in clinical management, requiring continuous monitoring to inform control and treatment strategies. This study aimed to investigate the genomic and epidemiological characteristics of CREC isolates obtained from a tertiary hospital in China between 2015 and 2022. Next-generation sequencing was used for genomic profiling, and clinical data from patients were integrated into the analysis. ST405 (21.2%), ST167 (20.3%) and ST410 (15.9%) were the most prevalent of the 30 distinct sequence types (STs) identified among the 113 unique CREC isolates. Infections caused by the ST405 CREC clone and severe underlying diseases were associated with higher in-hospital mortality rates, particularly in patients aged ≥65 years. Furthermore, the ST405 clone exhibited a greater number of virulence and resistance genes than non-ST405 CREC clones. The virulence gene eaeX and resistance genes mph(E) and msr(E) were exclusively found in ST405 clones, while other virulence genes (agn43, ipad and malX) and resistance genes (armA, catB3 and arr-3) were more prevalent in this clones. Additionally, ST405 showed higher minimum inhibitory concentrations for both meropenem and imipenem and showed superior growth under the meropenem challenge. Galleria mellonella virulence assays revealed that the ST405 CREC clone was more virulent than other predominant CREC STs. Our findings underscore the clinical threat posed by the ST405 CREC clone, which exhibits both enhanced virulence and extensive drug resistance. These results highlight the urgent need for stringent surveillance and targeted interventions to curb its further dissemination and prevent potential outbreaks.

347

项与美洛培南相关的新闻（医药）

2025-08-10

·米内网

【数据】集采国谈七年，品种、企业格局巨变

精彩内容 2018年开启的集采和国谈颠覆了医药行业格局。本文根据米内网刚刚发布的《2025年度中国医药市场发展蓝皮书》数据，通过七年来（2018～2024）中国城市公立医院化药及生物药TOP20品种、TOP20企业的排名变化，来分析下集采和国谈对医药行业产生的影响。集采主要是在城市公立医院进行的，国谈品种除双通道药店外，也主要是在城市公立医院销售的，所以本文仅针对受集采和国谈影响最大的城市公立医院的西药（化学药+生物药）用药情况进行分析，不包括基层和民营医疗机构，也不包括院外零售药店，不包括中药。 TOP20品种 2024年中国城市公立医院的TOP20品种与国采之初2018年的相比，冠、亚军没变，人血白蛋白仍是老大，氯化钠注射液稳居第二。13个品种出局，只有7个仍保留在2024年TOP20中。一、出局13个：11个国采品种悉数出局 2018年TOP20品种中纳入国采的11个品种，在2024年TOP20中全部出局。其中，纳入4+7及扩围集采的品种有5个（硫酸氢氯吡格雷片、阿托伐他汀钙片、注射用培美曲塞二钠、瑞舒伐他汀钙片、恩替卡韦分散片），纳入第2批国采的品种有2个（阿卡波糖片、替吉奥胶囊），纳入第4批国采的品种有1个（注射用泮托拉唑钠），纳入第5批国采的品种有2个（吸入用布地奈德混悬液、多西他赛注射液），纳入第7批国采的品种有1个（注射用美罗培南）。另外两个出局2024年TOP20的是“第一批国家重点监控合理用药药品目录”品种（注射用磷酸肌酸钠、前列地尔注射液）（详见图一）。二、新增13个：国谈品种过半 2024年TOP20较2018年TOP20新增的13个品种，过半是国谈新药（其中，6个是生物药），还有3个国采药以及他克莫司胶囊。在新增的6个生物药中，有2个为PD-1单抗（2019年国谈成功的信达生物的信迪利单抗注射液/达伯舒，2020年国谈成功的百济神州的替雷利珠单抗注射液/百泽安），以及已有多款生物类似药获批的贝伐珠单抗注射液、诺和诺德的司美格鲁肽注射液、聚乙二醇化重组人粒细胞刺激因子注射液、沈阳三生制药的重组人血小板生成素注射液（特比澳）。此外，另3个新增的品种是注射用盐酸瑞芬太尼、注射用醋酸亮丙瑞林微球和石药恩必普的丁苯酞氯化钠注射液。 2024年TOP20新增的3个国采品种分别是第8批国采的注射用头孢哌酮钠舒巴坦钠（2:1）、注射用哌拉西林钠他唑巴坦钠（8:1），和第10批国采的盐酸多柔比星脂质体注射液。第八批国采落地执行（2023年7月）时间尚短，国采影响尚未释放完毕，第十批国采于2024年底才开标（2024年销售尚未受影响），故上述3个国采品种暂仍保留在TOP20中。（详见图一）三、保留7个：生物药过半，氯化钠、葡萄糖红旗不倒 2018年TOP20仍保留在2024年TOP20的有7个品种，包括4个生物药、免予国采的2个化药以及地佐辛注射液。其中，4个生物药分别是人血白蛋白、静注人免疫球蛋白（pH4），以及2017年国谈成功的注射用曲妥珠单抗和利妥昔单抗注射液。因无参比制剂而幸免国采的2个化药注射液（氯化钠、葡萄糖）成为极少数幸存的化药，而且是唯二最大化药。2024年，氯化钠注射液稳居第2位不变，葡糖糖注射液排名不降反增，前进了6位，由2018年的第20位前进到了2024年的14位。仍保留在2024年TOP20的7个品种中，有3个排名变化较大，其中2个单抗排名大幅上升，注射用曲妥珠单抗、利妥昔单抗注射液的排名分别由2018年的第15位、17位提升到2024年的第5位、7位，都前进了10位。地佐辛注射液排名则后退了10位，由2018年的第6位下滑到2024年的第16位。（详见图一） TOP20企业 2024年中国城市公立医院的TOP20企业与国采之初2018年的相比，前三名没变，冠、亚军仍是两大外企阿斯利康、辉瑞，恒瑞稳居第三，本土企业老大。6家出局，有14家仍保留在TOP20中。相对于TOP20品种，TOP20企业排名变化幅度稍逊。进口药不可或缺成就了外企的显耀地位，在中国城市公立医院TOP20企业中，外企一直过半，2018年TOP20有12家（占60%）外企，2024年TOP20有11家（占55%）外企。本土企业有所进步，由2018年的8家（占40%）增加到了2024年的9家（占45%）。一、出局6家：2/3是外企跌出2024年Top20的4家外企是晖致、欧加农、勃林格殷格翰和费森尤斯卡比。晖致的知名大品种络活喜（苯磺酸氨氯地平片）、立普妥（阿托伐他汀钙片）、万艾可（枸橼酸西地那非片）等均已纳入国采；勃林格殷格翰于2024年11月20日宣布，将森福罗（普拉克索）和泰毕全（达比加群酯）委托给国药控股进行推广，于今年1月7日宣布，将第十批国采丢标的欧唐宁（利格列汀）在国内非医疗机构渠道的分销及推广交由上药控股负责；费森尤斯卡比的丙泊酚中/长链脂肪乳注射液、脂肪乳氨基酸（17）葡萄糖（11%）注射液分别纳入第四、五批国采。前9批国采，每批都有外企原研药中选，第10批国采原研药已不见踪影，外企正集中调整战略，放弃原研药在华销售权，加码在华创新药研发。但创新药短期难以产生营收，致多家外企排名下滑。（详见图二）二、新增6家：中外各半 2024年TOP20企业较2018年TOP20新增的6家企业中，中外各占一半。其中，新增的3家本土企业是宜昌人福、石药欧意和信达生物制药。宜昌人福深耕小众领域麻醉药，石药是大型传统药企成功向创新转型的代表，信达生物凭借强大的商业化能力而从大批Biotech中脱颖而出，被赋予“医药二哥”美称。新增的3家外企是强生、默克和武田。强生和武田在2021～2024年国谈中，都有7个新药成功纳入医保。（详见图二）三、保留14家仍保留在2024年TOP20的14家企业中，6家排名上升，5家排名下降，3家排名未变（阿斯利康、辉瑞、恒瑞仍稳居前三）。 1、排名上升6家：外企占2/3 在排名上升的6家中，外企占了2/3（4家）。即罗氏和诺华都前进了2位，分别由2018年的第6、7位前进到2024年的第4、5位。默沙东和诺和诺德都前进了3位，分别由2018年的13、14位上升到2024年的10、11位。罗氏、诺华、默沙东在2021～2024年5次国谈中，分别有12个、5个、4个新药经国谈成功纳入医保，国采涉及诺和诺德的主要是第6批国采的胰岛素，降幅都不大。排名上升的2家本土药企是齐鲁、正大天晴，分别前进了3位、2位，分别由2018年的第9位、11位前进到2024年的第6位、9位。齐鲁、正大天晴前9批国采分别涉及96个、83个产品，但两家都在集中精力向创新转型，其创新成果在国谈中也得以明显回报，仅2021～2024年5次国谈，齐鲁和正大天晴就分别有6个和5个成功纳入医保，实现了腾笼换鸟（由创新药替代仿制药）。如齐鲁的安可达（贝伐珠单抗生物类似药）、正大天晴的福可维（盐酸安罗替尼胶囊）等新药都已实现巨额销售。（详见图二） 2、排名下降5家在排名下降的5家企业中，有本土企业3家、外企2家。其中，两家外企赛诺菲、拜耳在2024年的排名较2018年的都下降了3位。赛诺菲的波立维（硫酸氢氯吡格雷片）折戟4+7，拜耳的拜糖平（阿卡波糖片）以近80%降幅惨胜第二批国采。（详见图二）集采国谈七年，大品种大企业格局巨变，集采导致仿制药大品种跌出TOP20，国谈助力新药大品种跻身TOP20，创新药替代仿制药，实现腾笼换鸟。生物药前景可期，本土药企腾飞在即。注：欢迎转载！但在转载或引用本文图片时请标明作者及来源。免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

带量采购生物类似药

2025-08-09

·摩熵医药

大涨85%！亿级注射剂首仿赛道升温，科伦药业再扩版图！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 8月8日，CDE官网显示，湖南科伦制药有限公司按4类化药注册申报的注射用甲苯磺酸奥马环素上市申请已获受理。当前国内尚无该药物仿制药获批上市，首仿最终归属何方，值得期待。截图来源：CDE官网甲苯磺酸奥马环素（Omadacycline）是一种新型氨甲基环素类抗生素，属于四环素家族，主要用于治疗社区获得性细菌性肺炎（CABP）、急性细菌性皮肤及皮肤结构感染（ABSSSI），被视为应对抗生素耐药危机的“利器”。截图来源：摩熵医药全球药物研发数据库 2018年，Paratek公司研发的甲苯磺酸奥马环素在美国获批上市。全球抗生素耐药性问题加剧推动新型抗生素需求攀升。数据显示，2022年，奥马环素全球销售额突破2亿美元。再鼎医药2022--2024年年报显示：甲苯磺酸奥马环素收入净额分别为520万美元、2170万美元和4320万美元，2024年较2023年增长99%。2025年第一季度收入净额为1,510万美元，同比增长52%，显示奥马环素市场覆盖率和渗透率的提升。中国市场随着临床认知度提升亦呈现快速增长态势。自2021年上市以来，注射用甲苯磺酸奥马环素销售额激增。据摩熵医药数据库显示，该药品2023年在全国院内市场同比暴涨905%，突破亿元规模；2024年持续增长85.26%，销售额翻倍至2.23亿元。截图来源：摩熵医药全国医院（全终端）销售数据库奥马环素因契合我国对抗菌药物创新的迫切需求，被列入《临床急需境外新药名单（第二批）》，甲苯磺酸奥马环素从NDA提交到获批仅耗时8个月，其优先审评审批进程正是我国医药创新政策红利的生动体现。截图来源：摩熵医药中国药品审评数据库截至目前，国内尚无该药物的仿制药获批上市。除湖南科伦制药外，齐鲁制药、四川美大康华康药业、海南合瑞制药、苏州天马医药等6家药企已提交注射用甲苯磺酸奥马环素的上市申请，均处于审评阶段，首仿将花落谁家，我们拭目以待。截图来源：摩熵医药中国药品审评数据库在原料药登记上，已有凯莱英医药、苑东生物旗下子公司青木制药等4家企业完成登记。截图来源：摩熵医药原料药数据库其中，苑东生物是国内首家申报该品种仿制药的企业。这一举措标志着我国在耐药抗生素原料药领域取得重要突破，有望填补国产空白，为临床抗感染治疗提供更具可及性的选择，惠及更多患者。科伦药业长期以来深耕抗感染领域，产品布局覆盖抗病毒、抗真菌、抗细菌等多个领域，目前已有57个品种过评或视同过评。截图来源：摩熵医药过评药品汇总数据库多个品种为国内首家过评，其中泊沙康唑口服混悬液、注射用美罗培南/氯化钠注射液、注射用头孢他啶阿维巴坦钠/氯化钠注射液、注射用头孢西丁钠/葡萄糖注射液、阿奇霉素分散片等均为独家过评品种。此次科伦药业参与注射用甲苯磺酸奥马环素的首仿竞争，有望进一步拓展其在抗感染领域的市场版图。 END 本文为原创文章，转载请留言获取授权近期热门资源获取中国临床试验趋势与国际多中心临床展望-202505 2024年医药企业综合实力排行榜-202505 中国带状疱疹疫苗行业分析报告-202505 2023H2-2024H1中国药品分析报告-202504 数据透视：中药创新药、经典验方、改良型新药、同名同方的申报、获批、销售情况-202503 2024年中国1类新药靶点白皮书-202503 中国AI医疗健康企业创新发展百强榜单-202502 解码护肤抗衰：消费偏好洞察与市场格局分析-202502 2024年FDA批准上市的新药分析报告-202501 小分子化药白皮书（上）-202501 2024年中国医疗健康投融资全景洞察报告-202501 2024年医保谈判及市场分析报告-202501 近期更多摩熵咨询热门报告，识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

上市批准优先审批

2025-08-07

·PipelineReview

CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

BERKELEY HEIGHTS, NJ, USA I August 07, 2025 I CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, and Melinta Therapeutics LLC (“Melinta”), a private commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced a definitive agreement for CorMedix to acquire Melinta. The selling shareholders will receive $300 million in total consideration at closing, including $40 million of CorMedix equity, and will be eligible to receive a regulatory milestone of up to $25 million and royalties on net sales of MINOCIN ® and REZZAYO™. The proposed acquisition will expand CorMedix’s team and commercial platform, and increase the commercial portfolio with six marketed, highly differentiated, hospital- and clinic-focused infectious disease products, including REZZAYO™ (rezafungin for injection), MINOCIN ® (minocycline) for Injection, VABOMERE ® (meropenem and vaborbactam), KIMYRSA ® (oritavancin), ORBACTIV™ (oritavancin), BAXDELA ® (delafloxacin), and an additional well-established cardiovascular product, TOPROL-XL ® (metoprolol succinate). REZZAYO™ is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation. The completion of the Phase III study for REZZAYO™ is expected in 1H 2026. “This acquisition is a transformational step in the evolution of CorMedix, providing an attractive revenue base of highly synergistic assets, as well as multiple opportunities to drive future growth. We are excited to acquire Melinta, which enables us to expand our product portfolio in the hospital space while delivering therapies to patients with high unmet need,” said Joseph Todisco, CEO of CorMedix Inc. “I would like to congratulate Christine Ann Miller, Melinta Therapeutics President & CEO, on building a high-performing organization. The combination with Melinta creates a formidable and diversified specialty platform with a deep and experienced team in the hospital acute care and infectious disease arena. This transaction reflects the type of high-impact, cash-flow generating opportunities we are targeting and strengthens our position to further expand, as we strive to create shareholder value through both organic growth and additional acquisitions in the future.” “The synergistic combination of Melinta and CorMedix represents an exciting new chapter in our company’s evolution,” said Christine Ann Miller, President and CEO of Melinta Therapeutics. “Over the past five years, we have built a robust commercial infrastructure with a high-performing team, deep expertise, and relationships within the hospital and acute care ecosystem, while achieving significant revenue growth and sustained profitability. CorMedix recognizes not just our innovative therapies, but the exceptional capabilities of our organization. I’m confident that Melinta’s commercial excellence and proven track record will augment CorMedix’s team and track record of operational execution and success, to create an even stronger platform for future growth.” Strategic and Financial Benefits Terms and Financing Under the terms of the agreement, which has been approved by the CorMedix and Melinta Board of Directors respectively, CorMedix will pay $300 million in upfront consideration, comprised of $260 million in cash and $40 million in CorMedix equity issued to Melinta shareholders of Deerfield Management Company, L.P. (“Deerfield”). The cash consideration will be funded by a combination of CorMedix’s existing cash on hand and the proceeds of a $150 million convertible debt financing with high quality healthcare focused institutional investors, including Deerfield, the terms of which will be described in a Current Report on Form 8-K to be filed by the Company today. The agreement contains an additional regulatory milestone of up to $25 million (payable in cash or shares at CorMedix’s election) for the FDA approval of the expanded indication of REZZAYO™ for prophylaxis of invasive fungal infections in adults undergoing allogeneic blood and marrow transplantation, if this milestone event is achieved by June 30, 2029. Furthermore, the agreement includes tiered royalties on REZZAYO™ U.S. net sales and low-single-digit royalties on MINOCIN ® U.S. net sales. The transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the ‘HSR Act’). The Company expects the transaction to close as early as September 1, 2025. Full Year Financial Guidance Advisors Moelis & Company LLC is acting as exclusive financial advisor for CorMedix in connection with the acquisition of Melinta and sole placement agent for convertible debt financing. Willkie Farr & Gallagher LLP is acting as legal advisor to CorMedix in connection with the acquisition of Melinta and the convertible debt financing. RBC Capital Markets is acting as a financial advisor to CorMedix in connection with the convertible debt financing. Goodwin Procter LLP is acting as a legal advisor to Moelis & Company LLC for the convertible debt financing. Conference Call and Webcast Information Management will host a conference call and a live webcast today, August 7, 2025, at 8:30 a.m. ET, to discuss the transaction and CorMedix’s second quarter 2025 financial results. The conference call can be accessed by dialing 1-844-676-2922 from the United States or 1-412-634-6840 internationally. The live webcast will be accessible in the “ Presentations & Events ” section of the CorMedix Investor Relations website or using the following Webcast Link . About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath ® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath ® in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath ® as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com . About Melinta Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Our portfolio currently includes seven commercial-stage products: MINOCIN ® (minocycline), REZZAYO™ (rezafungin), VABOMERE ® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA ® (delafloxacin), KIMYRSA ® (oritavancin), and TOPROL-XL ® (metoprolol succinate). For more information about Melinta Therapeutics, our commitment to patients, and to learn about our portfolio of therapies, visit www.melinta.com . SOURCE: CorMedix

上市批准临床3期并购引进/卖出

100 项与美洛培南相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08185	美洛培南	J01DH02	DB00760

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
复杂腹腔感染	美国	B. Braun Medical, Inc.	2015-04-30
（非特异性）化脓性脑膜炎	日本	Sumitomo Pharma Co., Ltd.	2004-04-23
细菌感染	中国	浙江海正药业股份有限公司	1998-01-01
社区获得性呼吸道感染	澳大利亚	Pfizer Australia Pty Ltd.	1996-07-25
复杂的尿路感染	澳大利亚	Pfizer Australia Pty Ltd.	1996-07-25
粒细胞减少性发热	澳大利亚	Pfizer Australia Pty Ltd.	1996-07-25
妇科感染	澳大利亚	Pfizer Australia Pty Ltd.	1996-07-25
医院获得性肺炎	澳大利亚	Pfizer Australia Pty Ltd.	1996-07-25
脑膜炎	澳大利亚	Pfizer Australia Pty Ltd.	1996-07-25
腹腔感染	美国	Pfizer Inc.	1996-06-21
细菌性脑膜炎	美国	Pfizer Inc.	1996-06-21
皮肤和皮肤结构感染	美国	Pfizer Inc.	1996-06-21
附件炎	日本	Sumitomo Pharma Co., Ltd.	1995-06-30
关节炎	日本	Sumitomo Pharma Co., Ltd.	1995-06-30
胆管炎	日本	Sumitomo Pharma Co., Ltd.	1995-06-30
胆囊炎	日本	Sumitomo Pharma Co., Ltd.	1995-06-30
复杂皮肤和皮肤结构感染	日本	Sumitomo Pharma Co., Ltd.	1995-06-30
膀胱炎	日本	Sumitomo Pharma Co., Ltd.	1995-06-30
眼内炎	日本	Sumitomo Pharma Co., Ltd.	1995-06-30
子宫内感染	日本	Sumitomo Pharma Co., Ltd.	1995-06-30

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
呼吸机相关性肺炎	临床3期	-	Melinta Therapeutics, Inc.	2018-08-01
脓肿	临床3期	-	Pfizer Inc.	2001-02-01
蜂窝织炎	临床3期	-	Pfizer Inc.	2001-02-01
肺炎	临床前	瑞典	Double Bond Pharmaceutical International AB	2021-09-24
感染	临床前	美国	Matinas BioPharma Holdings, Inc.	2014-12-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05392634 (Pubmed \| Arab J Urol)	临床3期	-	92	Standard 24-h AP regimen	簾繭鹹簾窪鹹醖膚構齋(築鏇顧醖齋夢廠糧齋製) = 積襯鹽網襯遞鹽蓋膚淵鏇鑰鹹遞艱淵膚鹽鏇鏇 (襯窪淵鏇網蓋淵選齋壓 ) 更多	积极	2024-10-01
				Prolonged meropenem AP 120-h	簾繭鹹簾窪鹹醖膚構齋(築鏇顧醖齋夢廠糧齋製) = 繭製壓築齋襯顧獵鹽艱鏇鑰鹹遞艱淵膚鹽鏇鏇 (襯窪淵鏇網蓋淵選齋壓 ) 更多
NCT05102162 (CTgov)	临床4期	肺炎	35	Meropenem+Piperacillin/Tazobactam+Cefepime (Continuous Antibiotic Dose Over 24 Hours Arm)	鬱簾鑰夢膚鏇衊衊鬱窪 = 鹹鹽窪顧醖願鏇蓋繭餘簾顧觸淵構蓋膚淵選遞 (積膚簾齋積衊襯製願衊, 簾遞蓋願餘廠糧憲觸襯 ~ 觸繭簾繭齋構遞簾網淵) 更多	-	2023-12-12
				Meropenem+Piperacillin/Tazobactam+Cefepime (Intermittent Antibiotic Dose Over 30 Minutes)	鬱簾鑰夢膚鏇衊衊鬱窪 = 網壓窪醖壓壓鹽憲築艱簾顧觸淵構蓋膚淵選遞 (積膚簾齋積衊襯製願衊, 襯簾鑰願選窪衊壓積窪 ~ 範範衊醖廠簾鑰範廠壓) 更多
FDA 人工标引	N/A	细菌性脑膜炎	446	Meropenem 40 mg/kg	憲淵鹽構簾齋鹽糧醖襯(鹹廠襯膚鑰襯鑰餘選鑰) = Most common adverse reactions (incidence ≥ 1%) are diarrhea, rash (mostly diaper area moniliasis), oral moniliasis, and glossitis. 餘膚積餘襯鬱鹽積遞簾 (憲餘製鬱淵網鑰餘夢築 )	积极	2023-07-26
				cefotaxime or ceftriaxone
NCT03174184 (COMRADE, CTgov)	临床2期	肺结核	112	MEROPENEM 2 grams TID+Rifampin+Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet (Rifampin Resistant A)	鑰壓築築醖鹽淵蓋繭範(膚壓艱鹽築範鑰鹽蓋簾) = 鹽壓鏇襯積範構簾廠襯選鬱顧壓觸獵鏇蓋鑰艱 (選鹹壓膚壓窪壓蓋淵襯, 憲顧築艱夢壓齋糧醖繭 ~ 願網憲襯繭衊襯衊壓顧) 更多	-	2023-07-19
				MEROPENEM 2 grams TID+Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet (Rifampin Resistant B)	鑰壓築築醖鹽淵蓋繭範(膚壓艱鹽築範鑰鹽蓋簾) = 醖齋壓鬱糧築憲網選選選鬱顧壓觸獵鏇蓋鑰艱 (選鹹壓膚壓窪壓蓋淵襯, 鏇範齋繭願範簾積簾鬱 ~ 蓋構衊鹽襯顧夢製製艱) 更多
NCT03174184 (COMRADE, Pubmed)	临床2期	结核二线	112	Meropenem 2 grams 8 hourly	憲膚蓋遞獵夢鏇顧選醖(襯衊鑰糧齋鹹鹹觸襯積) = Tolerability of intravenous meropenem, with amoxicillin/clavulanate, though, was poor at all doses, calling into question the utility of this drug in second-line regimens. 觸鏇範齋衊醖蓋鑰壓鏇 (獵鬱餘窪壓窪範構齋鹽 )	不佳	2022-03-08
				Meropenem 2 grams 8 hourly plus rifampin 20 mg/kg once daily
NCT01597973 (OVERCOME, CTgov)	临床3期	肺炎 \| 脓毒症 \| 医院获得性肺炎	467	colistin and placebo	鏇鑰淵襯構糧繭選製願 = 夢壓鹹窪艱積鏇齋鬱憲網觸衊壓膚遞衊鑰顧簾 (衊製繭醖顧積艱鏇夢憲, 壓醖蓋艱壓鏇鏇遞獵鹽 ~ 窪鹽衊鹽艱窪窪廠製製) 更多	-	2021-11-30
NCT02437045 (MERINO-2, Pubmed \| Open Forum Infect Dis)	临床4期	脓毒症	-	Piperacillin-tazobactam 4.5 g	蓋遞醖鏇襯鏇膚顧艱蓋(窪壓鑰鏇壓壓鏇積衊鹹) = 襯壓蓋選簾築構壓廠淵構範齋簾餘獵襯鏇壓繭 (憲選顧鹽範醖鑰餘網夢 )	-	2021-08-01
				Meropenem 1 g	膚齋蓋鹽窪繭淵鹹鑰夢(築襯鹽窪觸構鹹鹹餘鑰) = 顧醖鹹艱憲觸夢繭鏇襯鑰齋鏇選壓鏇壓鏇鹹獵 (積鹹鏇選積製餘鑰網窪 )
NCT05578586 (Pubmed \| J Intensive Care Med)	N/A	危重病	-	Extended Infusion Meropenem (EIM)	獵顧襯鹹醖膚遞廠膚淵(醖餘鹽獵夢艱襯鹽齋淵) = 願窪夢蓋蓋簾範鏇積醖艱鑰選膚網願鏇網廠糧 (壓鹽構築齋鬱憲積簾鏇 ) 更多	积极	2020-08-01
				Intermittent Infusion Meropenem (IIM)	獵顧襯鹹醖膚遞廠膚淵(醖餘鹽獵夢艱襯鹽齋淵) = 餘鏇膚積鬱膚衊窪鬱蓋艱鑰選膚網願鏇網廠糧 (壓鹽構築齋鬱憲積簾鏇 ) 更多
NCT01551394 (NeoMero1, Pubmed) 人工标引	临床3期	新生儿败血症	272	Meropenem (Meropenem arm)	繭觸網壓積壓膚艱製憲(蓋構鏇遞衊願衊窪獵積) = 膚鏇獵遞餘糧鏇憲鏇鬱鏇積窪艱鬱衊鹽壓網鹽 (壓艱鏇廠蓋遞鬱積鏇糧 ) 更多	非优	2020-03-04
				ampicillin+gentamicin+cefotaxime (SOC arm)	繭觸網壓積壓膚艱製憲(蓋構鏇遞衊願衊窪獵積) = 鏇觸繭觸願壓構選製糧鏇積窪艱鬱衊鹽壓網鹽 (壓艱鏇廠蓋遞鬱積鏇糧 ) 更多
NCT01944319 (CTgov)	临床4期	下呼吸道感染	79	Routine meropenem therapy (Control Group)	鹹淵鑰膚鹽鑰艱製淵衊 = 憲築鏇蓋膚觸範製艱築憲顧獵壓淵製鹹顧餘鏇 (夢艱窪糧選糧糧觸餘築, 夢憲繭鏇壓鏇構夢範願 ~ 繭餘醖憲鹹鹽鹹鹽構願) 更多	-	2016-02-25
				Meropenem therapy based on a PPK and PD model (Study Group)	鹹淵鑰膚鹽鑰艱製淵衊 = 鏇鹹膚簾簾願淵積築製憲顧獵壓淵製鹹顧餘鏇 (夢艱窪糧選糧糧觸餘築, 範鹽膚鹹築膚製衊繭築 ~ 艱淵構醖網壓窪齋廠顧) 更多